Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prevalence and seroprevalence of COVID-19 infection among older people: A scoping review based on population-based studies in 2020-2022

View ORCID ProfileJingxin Lei, Phyumar Soe
doi: https://doi.org/10.1101/2024.03.08.24303942
Jingxin Lei
1School of Population and Public Health, University of British Columbia, BC V6T 1Z4, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jingxin Lei
  • For correspondence: jingxin.lei{at}ubc.ca
Phyumar Soe
1School of Population and Public Health, University of British Columbia, BC V6T 1Z4, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Accurate estimates of the prevalence of infections play an important role in COVID-19 surveillance. Older people are known to have higher risks of severe outcomes after infection, but whether they also have a higher infection rate remains unclear. To obtain estimates of COVID-19 prevalence among older people, we synthesized evidence from RT-PCR-based prevalence and serological studies.

Methods We conducted a scoping review using a comprehensive search of MEDLINE (Ovid), Embase (Ovid), Europe PMC, ClinicalTrials.gov, and the WHO COVID-19 Research Database from December 2019 to Oct 2022. We included population-based cross-sectional (sero)prevalence studies among older people (i.e., people aged >= 65 +/-5 years) who were tested for SARS-CoV-2 infection using RT-PCR tests, antigen tests, or serological tests. Studies that were conducted solely in institutional housing were excluded. Eligible studies were extracted and critically appraised. We described and mapped the prevalence (tested by RT-PCR or antigen tests) and seroprevalence (tested by serological tests) by geographical area and time. We then compared the estimated prevalence with WHO-reported prevalence and the prevalence among younger age groups from the same study.

Results We identified 202 (sero)prevalence estimates from 126 studies, covering 50 countries up to October 2022. Of the 126 studies, 28 studies estimated RT-PCR-based prevalence; 104 studies estimated seroprevalence, ranging from 0% in Jordan to 22.5% in the United States in 2020, from 0.41% in Brazil to 98% in Chile in 2021. In the year 2020, prevalence of COVID-19 ranged from 0.0006% in China, to 52.8% in Brazil, while in 2021, prevalence ranged from 0.06% in England to 41.1% in Brazil. The ratio of the reported prevalence to estimated prevalence ranged from <0.01 to 77.50, where 86% (24/28) studies estimated a higher prevalence than WHO reported and half of them estimated >10 times higher prevalence. One third of studies (32%, 9/28) estimated a higher prevalence in older people compared with younger people.

Conclusions Our findings suggest that underreporting of COVID-19 cases among older people may exist extensively worldwide. Compared with younger groups, older people were less likely to be infected with COVID-19 in two thirds of the studies through the first two years of the pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 09, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence and seroprevalence of COVID-19 infection among older people: A scoping review based on population-based studies in 2020-2022
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prevalence and seroprevalence of COVID-19 infection among older people: A scoping review based on population-based studies in 2020-2022
Jingxin Lei, Phyumar Soe
medRxiv 2024.03.08.24303942; doi: https://doi.org/10.1101/2024.03.08.24303942
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Prevalence and seroprevalence of COVID-19 infection among older people: A scoping review based on population-based studies in 2020-2022
Jingxin Lei, Phyumar Soe
medRxiv 2024.03.08.24303942; doi: https://doi.org/10.1101/2024.03.08.24303942

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)